Skip to main content
Premium Trial:

Request an Annual Quote

Texas A&M Wins $1M Grant to Link Gene Variants in Cattle to Disease Resistance, Other Traits

NEW YORK, Feb. 14 (GenomeWeb News) - TexasA&MUniversity's Collegeof Veterinary Medicinehas received a $1 million, two-year grant from the Robert J. and Helen C. Kleberg Foundation to study genetic variation in cattle, the institution said last week.


Researchers led by James Womack, director of the Center for Animal Biotechnology and Genomics at the college, plan to study gene variants contributing to disease resistance and susceptibility, reproduction, lactation, growth, bone structure, fat deposition, as well as altitude and heat tolerance. The diseases to be studied include bovine spongiform encephalopathy, Johne's disease, foot and mouth disease, and Rift Valley fever.


The scientists will focus on selected breeds of cattle, including European and Asian ones. One project will focus on developing bioinformatics tools for data analysis.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.